Lilly reports promising 52-week results from TOGETHER-PsA trial in PsA

​

Lilly has reported promising 52-week results from the Phase IIIb TOGETHER-PsA trial assessing Taltz alongside Zepbound for active PsA in adults with overweight or obesity.

The post Lilly reports promising 52-week results from TOGETHER-PsA trial in PsA appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.